Cellular Immunotherapy Global Market Report 2024

The cellular immunotherapy market size has grown rapidly in recent years. It will grow from $4.99 billion in 2023 to $5.78 billion in 2024 at a compound annual growth rate (CAGR) of 15.9%. The growth observed during the historical period can be attributed to advancements in cancer treatment, documented clinical success stories, regulatory approvals, and the increasing incidence of targeted diseases.

The cellular immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $9.95 billion in 2028 at a compound annual growth rate (CAGR) of 14.6%. The anticipated growth in the forecast period can be attributed to the expansion of cellular immunotherapy into solid tumors, enhancements in manufacturing processes, the development of healthcare infrastructure, and increased research funding. Key trends expected in the forecast period encompass heightened investments in research and development, the availability of valuable clinical trial data, and the exploration of combination therapies.

The growth of the cellular immunotherapy market is being propelled by increasing research and successful clinical trials in the field. Companies are dedicated to developing new cellular immunotherapies to address various diseases. As of April 2022, there were 2,756 active cell therapy drugs globally, a 36% increase from 2021, indicating rapid growth in this sector. This growth, particularly in clinical and preclinical stages, is expected to expand the cellular immunotherapy landscape, driving market revenues higher.

The key therapies within cellular immunotherapy include tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, and natural killer (NK) cell therapy. Tumor-infiltrating lymphocyte (TIL) therapy is a form of adoptive cellular therapy involving the extraction of lymphocytes that have infiltrated tumors, their cultivation and amplification in vitro, and subsequent infusion into patients for therapeutic purposes. This therapy finds application in various primary indications, including b-cell malignancies, prostate cancer, renal cell carcinoma, liver cancer, non-Hodgkin lymphoma, among others, and is utilized in the treatment of conditions such as prostate cancer, breast cancer, skin cancer, ovarian cancer, brain tumors, lung cancer, and more.

The cellular immunotherapy market research report is one of a series of new reports that provides cellular immunotherapy market statistics, including cellular immunotherapy industry global market size, regional shares, competitors with a cellular immunotherapy market share, detailed cellular immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the cellular immunotherapy industry. This cellular immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The prevalence of cancer is another factor expected to drive the growth of the cellular immunotherapy market. Cancer is a group of diseases characterized by uncontrolled cell growth, spurring research and investment in cancer therapies, including cellular immunotherapies. These therapies leverage the patient's immune system to combat cancer cells, contributing to the rise of cellular immunotherapies. In 2021, the United States saw an estimated 1.9 million new cancer cases and 608,570 cancer-related deaths. This underscores the growing demand for effective cancer treatments, further boosting the cellular immunotherapy market.

The high cost of cellular immunotherapies poses a significant hindrance to market growth. CAR-T therapy, a type of cellular immunotherapy, is costly, with treatments like Yescarta and Kymriah priced over $350,000 per treatment in the USA. This cost is often unaffordable for many patients, especially those with lower incomes, leading to reduced demand and negatively impacting the market.

Companies in the cellular immunotherapy market are focusing on the development of off-the-shelf allogeneic therapies to improve cancer treatment. These therapies use donor cells rather than the patient's cells, offering benefits such as cost-effectiveness, large-scale production, speed, and quality control. Novartis, for example, received expedited FDA approval for Kymriah to treat adult patients with relapsed or refractory follicular lymphoma. Acepodia initiated a phase 1 clinical trial for ACE1702, an allogeneic, off-the-shelf NK cell therapy to treat solid tumors.

Major companies in the cellular immunotherapy market are also investing in innovative technologies like T-Charge to enhance their profitability. T-Charge, introduced by Novartis, maintains the critical properties of T cells, resulting in improved proliferative capacity, fewer exhausted T cells, and better treatment outcomes with reduced side effects.

In August 2021, BioNTech, a German biotechnology company, acquired Kite Pharma, a biotechnology company, to expand its immunotherapy pipeline. This acquisition provides BioNTech with Kite's laboratory and unique TCR platform, allowing the company to accelerate its immunotherapy research and development capabilities. Kite Pharma, based in the US, is known for developing cancer immunotherapy products.

Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd., Green Cross Corp, AstraZeneca PLC, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics PLC, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

North America was the largest region in the cellular immunotherapy market in 2023. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cellular immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The cellular immunotherapy market includes revenues earned by entities by inventing, developing, administering, and understanding engineered immune effector cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.